Loading clinical trials...

Comprehensive HIV and Harm Prevention Via Telehealth | Clinical Trials | Clareo Health

RECRUITINGNA

Comprehensive HIV and Harm Prevention Via Telehealth

Comprehensive HIV and Harm Prevention Via Telehealth: CHARIOT, a Randomized Controlled Trial

NCT05897099•University of Miami

Summary

The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•age 18 or older
•able to speak English or Spanish
•willing and able to sign informed consent, provide locator information and medical records release
•non-reactive result on rapid HIV test
•use of SSP to exchange syringes 2 times in the past 3 months
•planning to stay in the area for 12 months

Exclusion Criteria

•reactive HIV test
•currently on medications for opioid use disorder (MOUD) by urine drug screen
•currently on PrEP by self-report
•Principal or site investigator discretion
•currently in prison or jail
•current enrollment in Clinical Trials Network 121
•receipt of tele-harm reduction in previous 3 months
•signs or symptoms of acute HIV infection

Locations (2)

IDEA Miami

Miami, Florida, United States

IDEA Syringe Services Program

Miami, Florida, United States

Key Dates

Start Date

October 7, 2024

Primary Completion Date

March 31, 2028

Completion Date

May 31, 2028

Last Updated

February 17, 2026

Enrollment

350

ESTIMATED participants

Conditions

HIV Infections

Interventions

Comprehensive Tele-harm Reduction

BEHAVIORAL

Off-site Linkage to HIV Prevention

BEHAVIORAL

Contacts

Hansel Tookes, MD

CONTACT

3052431615 hetookes@med.miami.edu

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Comprehensive HIV and Harm Prevention Via Telehealth

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Skeletal Muscle Energetics and Fatiguability in Older Individuals

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)